50,000 Shares in Sionna Therapeutics, Inc. $SION Acquired by Seven Grand Managers LLC

Seven Grand Managers LLC purchased a new position in shares of Sionna Therapeutics, Inc. (NASDAQ:SION) during the fourth quarter, HoldingsChannel reports. The firm purchased 50,000 shares of the company’s stock, valued at approximately $2,057,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Viking Global Investors LP raised its stake in Sionna Therapeutics by 8.2% during the 2nd quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock worth $55,436,000 after buying an additional 242,427 shares during the period. Vanguard Group Inc. raised its stake in shares of Sionna Therapeutics by 3.7% in the fourth quarter. Vanguard Group Inc. now owns 1,184,951 shares of the company’s stock worth $48,749,000 after purchasing an additional 41,797 shares during the last quarter. Jennison Associates LLC raised its stake in shares of Sionna Therapeutics by 11.8% in the fourth quarter. Jennison Associates LLC now owns 1,115,278 shares of the company’s stock worth $45,883,000 after purchasing an additional 117,903 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Sionna Therapeutics by 20.1% in the fourth quarter. Geode Capital Management LLC now owns 380,042 shares of the company’s stock worth $15,638,000 after purchasing an additional 63,478 shares during the last quarter. Finally, Soleus Capital Management L.P. raised its stake in shares of Sionna Therapeutics by 56.7% in the second quarter. Soleus Capital Management L.P. now owns 376,000 shares of the company’s stock worth $6,524,000 after purchasing an additional 136,000 shares during the last quarter.

Sionna Therapeutics Stock Up 1.3%

Shares of Sionna Therapeutics stock opened at $43.43 on Thursday. The company has a market cap of $1.96 billion, a PE ratio of -22.50 and a beta of 1.35. The business has a 50 day moving average price of $40.02 and a 200-day moving average price of $39.77. Sionna Therapeutics, Inc. has a 52 week low of $12.55 and a 52 week high of $48.44.

Sionna Therapeutics (NASDAQ:SION) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). As a group, research analysts anticipate that Sionna Therapeutics, Inc. will post -2.57 EPS for the current year.

Wall Street Analysts Forecast Growth

SION has been the subject of several analyst reports. Lifesci Capital raised Sionna Therapeutics to a “strong-buy” rating in a research note on Wednesday, February 25th. Citigroup initiated coverage on Sionna Therapeutics in a research note on Tuesday, February 24th. They issued an “outperform” rating for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Sionna Therapeutics in a research note on Friday, May 8th. Wedbush initiated coverage on Sionna Therapeutics in a research note on Tuesday, May 5th. They issued an “outperform” rating and a $53.00 price objective for the company. Finally, Guggenheim increased their price objective on Sionna Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Three equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Sionna Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $53.22.

Insider Buying and Selling

In related news, Director Orbimed Advisors Llc sold 184,639 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $46.22, for a total transaction of $8,534,014.58. Following the completion of the sale, the director directly owned 2,671,822 shares of the company’s stock, valued at approximately $123,491,612.84. This trade represents a 6.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 184,639 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $46.22, for a total value of $8,534,014.58. Following the sale, the director directly owned 2,671,822 shares of the company’s stock, valued at $123,491,612.84. The trade was a 6.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,717,760 shares of company stock valued at $77,562,902 over the last ninety days. 3.90% of the stock is currently owned by company insiders.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.